INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Other Events
Item 8.01 Other Events
that it had entered into an exclusive license and distribution
agreement with Densmore Pharmaceutical International, a company
based in Monaco for the distribution of its Zestra(R) product in
France and Belgium. to the Densmore agreement, Densmore shall
provide Innovus with an up-front payment and has minimum annual
purchase requirements for Zestra(R) during the term of the
agreement.
this Current Report on Form 8-K.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press release issued May 16, 2017.
|
|
About INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV)
Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe. INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Recent Trading Information
INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) closed its last trading session down -0.0140 at 0.0980 with 1,562,294 shares trading hands.
